Merck Return on Tangible Equity 2010-2023 | MRK
Current and historical return on tangible equity values for Merck (MRK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Merck Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-12-31 |
$0.37B |
$-1.57B |
47.62% |
| 2023-09-30 |
$4.61B |
$0.92B |
199.83% |
| 2023-06-30 |
$3.11B |
$-2.12B |
120.79% |
| 2023-03-31 |
$13.03B |
$5.84B |
433.32% |
| 2022-12-31 |
$14.52B |
$4.59B |
2029.21% |
| 2022-09-30 |
$15.26B |
$2.00B |
-796.55% |
| 2022-06-30 |
$16.58B |
$-0.39B |
-1097.58% |
| 2022-03-31 |
$14.18B |
$-3.33B |
-1192.35% |
| 2021-12-31 |
$13.05B |
$-5.94B |
-579.70% |
| 2021-09-30 |
$7.20B |
$3.62B |
-270.45% |
| 2021-06-30 |
$5.57B |
$0.89B |
-101.67% |
| 2021-03-31 |
$7.03B |
$-7.57B |
-88.68% |
| 2020-12-31 |
$7.07B |
$-7.58B |
-83.92% |
| 2020-09-30 |
$11.52B |
$-7.66B |
-136.61% |
| 2020-06-30 |
$10.48B |
$-8.89B |
-135.50% |
| 2020-03-31 |
$10.15B |
$-9.56B |
-149.34% |
| 2019-12-31 |
$9.84B |
$-7.62B |
-205.97% |
| 2019-09-30 |
$9.31B |
$-4.86B |
-233.26% |
| 2019-06-30 |
$9.36B |
$-5.13B |
-421.47% |
| 2019-03-31 |
$8.40B |
$-1.50B |
-1557.53% |
| 2018-12-31 |
$6.22B |
$-4.48B |
1728.98% |
| 2018-09-30 |
$3.35B |
$2.22B |
166.97% |
| 2018-06-30 |
$1.34B |
$1.59B |
49.57% |
| 2018-03-31 |
$1.58B |
$2.10B |
43.69% |
| 2017-12-31 |
$2.39B |
$2.10B |
55.59% |
| 2017-09-30 |
$2.85B |
$5.02B |
57.04% |
| 2017-06-30 |
$5.09B |
$5.24B |
101.06% |
| 2017-03-31 |
$4.35B |
$4.87B |
85.97% |
| 2016-12-31 |
$3.92B |
$4.84B |
77.98% |
| 2016-09-30 |
$5.49B |
$5.19B |
111.43% |
| 2016-06-30 |
$5.13B |
$5.32B |
109.71% |
| 2016-03-31 |
$4.61B |
$4.75B |
105.04% |
| 2015-12-31 |
$4.44B |
$4.44B |
105.05% |
| 2015-09-30 |
$10.78B |
$4.19B |
154.66% |
| 2015-06-30 |
$9.85B |
$4.18B |
111.04% |
| 2015-03-31 |
$11.17B |
$4.10B |
90.79% |
| 2014-12-31 |
$11.92B |
$15.41B |
73.32% |
| 2014-09-30 |
$5.39B |
$11.79B |
32.71% |
| 2014-06-30 |
$5.61B |
$17.90B |
33.55% |
| 2014-03-31 |
$4.52B |
$19.93B |
29.80% |
| 2013-12-31 |
$4.40B |
$16.22B |
31.47% |
| 2013-09-30 |
$4.53B |
$12.88B |
33.57% |
| 2013-06-30 |
$5.14B |
$11.57B |
36.15% |
| 2013-03-31 |
$6.02B |
$15.29B |
40.72% |
| 2012-12-31 |
$6.17B |
$14.25B |
44.02% |
| 2012-09-30 |
$6.76B |
$15.72B |
51.76% |
| 2012-06-30 |
$6.72B |
$13.90B |
58.34% |
| 2012-03-31 |
$6.95B |
$12.16B |
68.36% |
| 2011-12-31 |
$6.26B |
$10.49B |
71.04% |
| 2011-09-30 |
$4.22B |
$9.55B |
56.77% |
| 2011-06-30 |
$2.87B |
$8.48B |
50.40% |
| 2011-03-31 |
$1.60B |
$6.73B |
38.93% |
| 2010-12-31 |
$0.86B |
$4.97B |
28.06% |
| 2010-09-30 |
$7.84B |
$2.61B |
349.84% |
| 2010-06-30 |
$10.92B |
$2.16B |
147.07% |
| 2010-03-31 |
$11.73B |
$2.50B |
97.18% |
| 2009-12-31 |
$12.85B |
$1.69B |
78.24% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$317.566B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
